Computer Simulation of Speciation of Trivalent Aluminum, Gadolinium and Yttrium Ions in Human Blood Plasma by Jakovljevic, Ivan et al.
861Acta Chim. Slov. 2013, 60, 861–869
Jakovljevi} et al.:  Computer Simulation of Speciation of Trivalent Aluminum, ...
Scientific paper
Computer Simulation of Speciation of Trivalent Aluminum,
Gadolinium and Yttrium Ions in Human Blood Plasma
Ivan Jakovljevi},1 \or|e Petrovi},2 Ljubinka Joksovi},1 Ivan Lazarevi}3
and Predrag \ur|evi}1,*
1 Faculty of Science, University of Kragujevac, P.O.Box 60, 34000 Kragujevac, Serbia, 
2 Institute of Nuclear Science ’’VIN^A’’, Laboratory for Radioisotopes P.O. Box 522, 11001 Belgrade, Serbia
3 CBRN Training Center of the Serbian Armed Forces, 37000 Kru{evac, Serbia
* Corresponding author: E-mail: preki@kg.ac.rs
Received: 31-07-2013
Abstract
The speciation of Al3+, Gd3+ and Y3+ ions in human plasma has been studied by computer simulation using the program
HySS2009. A literature computer model of blood plasma was updated and comprised 9 metals, 43 ligands and over
6100 complexes. To this model critically evaluated data of Al3+, Gd3+ and Y3+ constants with blood plasma ligands have
been added. Low molecular mass (LMM) speciation of Al3+ ion strongly depends upon the chosen equilibrium model of
the metal – phosphate and metal – citrate systems. The obtained computer simulation of LMM speciation data of Al3+
ion were: AlPO4Cit (40.7%), AlPO4CitOH (22.9%), AlCitOH (19.2%) and AlPO4(OH) (12.7%) (% of total LMM Al
species pool); for Gd3+ ion: GdAspCit (30%) and GdCit(OH)2 (20%) (% of total [Gd]) and for Y3+ ion: YCit (48%),
Y(CO3)2 (32%) and Y(CO3) (11%) (% of total [Y]). Citrate appears as the important binding and mobilizing ligand for
all examined ions, while the dominating species are the ternary ones.
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1. Introduction
Aluminum is generally regarded as toxic or detri-
mental element.1 Nevertheless, its compounds are widely
used in areas from medicine to car industry. Normally, des-
pite oral intake ranged from 5 to 10 mg daily (food, food
additives, drinks, atmospheric dust) aluminum is very little
absorbed into serum and tissues (less than 1% of intake do-
se).1,2 Normal serum levels are lower than 0.05 μmol L–1.1,2
However, high levels of aluminum (>3 μmol L–1 ) may ac-
cumulate in tissues of patients who have renal insuffi-
ciency or kidney failure and are treated by dialysis fluid
that contains aluminum or are given aluminum based gels
to control high plasma phosphate level. These patients may
develop blood, bone, brain diseases which at least in part
may be linked to the excess of the aluminum.1,2
In blood, aluminum is transported by transferrin to
lungs, liver, bones and other tissues including brain.3 In
blood aluminum may exist as bound to proteins (transfer-
rin, albumin), low-molecular mass ligand complexes
(LMM) and as free ion.4 Its chemical form is important
for its transport to tissues and cells, accumulation and ex-
cretion, thus the knowledge of identity, stability and con-
centration of various aluminum species is necessary for
understanding its metabolic pathways.5
Gadolinium and yttrium ions may be present in blood
as a result of medical treatment from imaging diagnostic
procedures in MRI where gadolinium is used as a contrast
agent and during the therapy of cancer where 90Y is widely
used.6,7 In nature, 90Y cannot be found, except in the case of
contamination or uncontrolled and rapid clearance of the pa-
tient. Toxic effects of parenterally introduced gadolinium
and yttrium chelates are numerous.8,9 Non-complexed gado-
linium is unsuitable for clinical use as it may form precipita-
tes which could exist for long periods in the body. The bioc-
hemical effects induced by simple gadolinium salts involve
the interference with calcium-depending processes and cal-
cium entry into cells. Free gadolinium ion can form mineral
emboli in the circulation which may be deposited in tissues
like muscle, skin, liver, bone and other organs. The emboli
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consist of a complex gadolinium phosphate, carbonate or
hydroxide.10,11 Phagocytosis of emboli may lead to cell
death due to blocking of macrophage function. Insolubility
and toxicity of gadolinium is eliminated by forming either
macrocyclic or linear chelates. The chelates are used as MRI
contrast agents and believed to be safe. The side effects may
occur owing to dissociation of Gd-ligand complex into me-
tal ion and ligand. This process is facilitated by endogenous
metals like iron, zinc, copper and calcium and by endoge-
nous acids.12 Gadolinium contrast agents may cause nephro-
toxicity and acute renal failure. Moreover after exposure to
gadolinium based contrast agents, patients with renal insuf-
ficiency may develop nephrogenic systemic fibrosis with
scleroderma-like changes in the skin and connective tissues
which has sometimes been fatal.8
90Y obtained from the 90Sr–90Y generator system
finds widespread use in the cancer treatment in the form
of radiopharmaceutical chelate.13 As other radiopharma-
ceuticals yttrium is administered by intravenous injection.
Yttrium chelates (DTPA, DOTA, etc.) are very stable and
usually safe for use. However in blood plasma dissocia-
tion may occur by the similar mechanism as in the case
gadolinium chelates. Yttrium may form particular emboli
consisting mainly of phosphate, carbonate or hydroxide
species. The chemical forms and their concentration le-
vels determine the fate of both gadolinium and yttrium
ions in the organism.14,15 It is the reason of detailed study
of their speciation by computer simulation. 
Direct measurement of concentrations of various
forms of aluminum, gadolinium and yttrium in blood and
other human tissues is difficult owing to low concentration
of these ions. Some well-established methods and their
properties used for the analysis of Al were reviewed in se-
veral excellent reviews and are summarized in Table 1.16–19
Data presented in Table 1 show that main HMM Al
species is its transferrin complex, while Al – citrate species
were identified as main LMM complexes. Significant num-
ber of studies determined only percentage of total Al bound
in LMM complexes without any speciation. Any attempt to
obtain the chemical speciation information by using direct
analytical way with methods given in Table 1 results in un-
controlled changes of labile Al species so that the obtained
results reflect more the analytical procedure than the distri-
bution of the native species in the samples. In such cases the
sole possible speciation techniques is of indirect nature,
through calculations based on the simulation models.
In the literature, numerous methods for the analysis
of Gd-based MRI contrast agents in several biological ma-
trices are described. To investigate Gd-based contrast
agents with the aim to study toxicity, only the total con-
centration of gadolinium were commonly determined in
biological fluids, such as plasma, serum, urine and faces,
by elemental techniques, such as ICP-OES, ICP-MS or
AAS.30–35 To gather more detailed information about the
Gd species, chromatographic or electrophoretic techni-
ques are required to separate the particular gadolinium
compounds and to detect them individually. Several ap-
proaches are described in the literature, employing a va-
riety of separation techniques, coupled to optical, element
and mass detectors.36–45 Experimental data for the deter-
mination of gadolinium in plasma are based on the addi-
tion of gadolinium contrast agents in the blood plasma of
healthy persons with subsequent determination of total
Gd3+. Achieved limit of detection was at best 0.01–0.1pg
mL–1 while limit of quantitation was in the range 1.3–5.8
ng mL–1 depending on applied method. 
Experimental data for determination of yttrium in
human samples and blood are not developed as those for
Table 1. Overview of experimental methods for the determination of Al species in human serum
Analytical 
Type of sample
Al-HMM Al-LMM
Method Species (%) Species (%)
Ref.
ICP-ETAAS Uremic serum: – 12.9/13.3 20
Stored/Fresh
HPLC-ETAAS Healthy controls 90 (Al-Tfn) 12±5 (Al-Cit) 21
(Spiked serum)
26Al and AMS Healthy controls – <5% 22
(Spiked serum)
GFC-FAAS Healthy controls – 14.5±3 23
Normal renal function 16.2±4
Renal-dialysis patients 19.7±4
FPLC-ETAAS Healthy controls – 15–19 (Al-Cit) 24
(Spiked serum)
HPLC and Healthy controls 79.1±7.0 19.6±3.6 25
Zeeman AAS Exposed 91.3±3.3 8.7±3.2
HPLC Healthy controls – 20 26
– Healthy controls – < 5 (Al-Cit) 27
(Spiked serum)
– Healthy controls 80 (Al-Tfn) 5 28
FPLC-ICP-MS Healthy controls – 10 29
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aluminum and gadolinium. So far limited data exist for
the biodistribution of yttrium in mice using radioactive
methods.46,47
Existing experimental methods cannot identify and
quantify most of the Al-, Gd- and Y-LMM species in serum,
thus the speciation must be based on the computer simula-
tion. These simulations were subject of intensive interest by
various research groups. The study of Al(III) speciation in
human blood plasma by computer simulation was perfor-
med by several research groups mainly using the program
ECCLES.48–55 These calculations were based on the as-
sumption that aluminum belongs to the class of non-exc-
hangeable elements (ie with slow uptake or dissociation
from transferrin) according to May et al.56 This means that
percentage of metal appearing in a given LMM species is
constant regardless of the exact free metal concentration
that exists in equilibrium with transferrin. Practically, the
concentration of LMM complex is directly proportional to
the free metal concentration since the free ligand concentra-
tion is not significantly affected by complexation owing to
very low free metal concentration. Thus, the distribution of
Al3+ is independent of metal concentration in the concentra-
tion range 10–15–10–5 mol L–1. So far obtained results for
speciation of aluminum in human plasma are summarized
in Table 2. From Table 2 it can be seen that speciation is de-
pendent on the assumed aluminum ion binding to transfer-
rin and on the stability constants of citrate and soluble
phosphate complexes. Controversy still exists whether
phosphates or citrates are dominating species.
Majority of the studies identified Al – citrate species as
the dominating ones, however, in some studies Al – phospha-
te species were found to be dominant ones. Careful analysis
of blood plasma database data is needed to resolve the prob-
lem. It seems that inclusion in the database only the species
relevant to physiological conditions, and large number of ter-
nary species may rectify the problem. Indeed, Harris et all
have reconsidered previous Harris’s data and concluded that
if Al –phosphate equilibrium data are limited only to species
relevant to physiological conditions and low Al free concen-
tration in plasma, then Al – citrate species are the dominant
ones while Al – phosphates become insignificant.53,55
The study on Gd(III)-ion speciation in human blood
plasma was performed by Jackson et al but they used a single
phase model in which the insoluble species of Gd were not
considered and some important macromolecular and ternary
complexes were not included.57 Webb et al studied Gd(III)
speciation in GI tract, but precipitates were again not consi-
dered.59 Yue Wang et al studied Gd(III) speciation in human
interstitial fluid with precipitate species and some important
new complexes being considered.60 They used a total con-
centration of gadolinium in range from 1.2 × 10–9 mol L–1 to
2.2 × 10–2 mol L–1 and the results are given in Table 3.
Table 2. Literature data on bio-distribution of Al(III) in blood plasma by computer simulations 
Total Al concentration 5 × 0–1 (1.8–2.5)
3 × 10–6 9 × 10–8 3 × 10–6 2.2 × 10–13 1 × 10–6 3 × 10–6(mol L–1) –5 × 10–3 × 10–13
% of total Al bound to transferrin 57 63 77 80 80 81 83 93
Al(OH)3 51 – – – – 4 – –
AlPO4 41.5 62 – 1.5 – 2 – –
Al2PO4(OH)2 7.2 – – – – – – –
AlCitOH 23 – – 3 – 10 – –
AlPO4CitH 10 – – – – – – –
AlCit(OH)2 – – – 94 51 – – –
AlOxa(OH)2 1.4 – – – – – – –
AlPO4OH – – – – 21 80 – –
AlPO4Cit, AlPO4CitOH – – – – 28 – – –
Al(OH)4 – – – – – 3 – –
Al-Citrate (all forms) – – 80 – – – 98 88
Al-Hydroxide (all forms) – – – – – 2 8
Al-Phosphate (all forms) – – 20 – – – – 2
Reference 48 49 50 51 52 53 54 55
%
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Table 3. Literature data on bio-distribution of Gd(III) in blood plasma by computer simulations 
Total Gd concentration (mol L–1) 1.2 × 10–9 1.0 × 10–7 5.99 × 10–4 2.07 × 10–2 2.2 × 10–2
Gd(HSA) 29.6 29.6 29.8 33.6 8.5
Gd(Oxa) 18.2 18.2 18.3 14.9 1.2
Gd(Cit)(Lac) 10.0 10.0 9.9 9.5 1.7
Gd(Cit)(Leu) 7.9 7.9 7.8 7.4 1.2
Gd(Cit)(Asp) 7.7 7.7 7.6 5.3 <1
Gd3(OH)4 <1 <1 <1 1.0 78.9
Gdfree 5.4 5.4 5.5 6.5 2.6%
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From the Table 3 one can see that the main ligands
which complexed gadolinium are albumin, oxalate and
ternary complexes citrate with lactate, leucinate and as-
partate. With increasing the total concentration of gadoli-
nium to 2.2 × 10–2 mol L–1 the main ligand becomes
hydroxide.
There are not many papers in which a computer spe-
ciation of yttrium in blood plasma was described. De Witt
et al performed computer modeling of complex yttrium-
EDTMP in blood plasma.61 Concentrations used in simu-
lation far exceed concentrations that are employed in the
treatment of bone cancer treatment. Results of computer
modeling by program ECLLES are given in Table 4.
1. 2. The human blood plasma model 
and speciation calculation
There are two general approaches to simulate complex
equilibria systems (a) Gibbs energy minimization and (b)
equilibrium constant method. The equilibrium constant met-
hod is widely used and is based on the solution of a set of
equilibrium conditions satisfying stoichiometric mass balance
equations. To this end we used Windows based computer pro-
gram HySS2009 with graphical interface.62 The program is
readily available, data input is straightforward and simple, and
output is produced as both graph and table of concentrations. 
The mathematical algorithm of the HySS program is
based on solving the stoichiometric equation
formula (1)
t = 1 + m   number of components
j = 1 + n   number of reactions (products)
βj = 1 + n  – formation constant of particular product, j
νji – stoichiometric coeficients, νji = 1 for j = i and 
j ≤ m and νji = 0 for j ≠ i and i ≤ m (first m products
are identical to components)
Ak – relative amount of the insoluble species, k, formed
[Ri] – free concentration of components
To calculate m free concentrations [Ri], i = 1 + m
the equation (2) is solved
(2)
where TRi
calc is calculated from right-hand side of Eq(1). TRi
in Eq (2) are experimental total concentration of reactants.
Table 4. Literature data on bio-distribution of Y(III) in blood plasma by computer simulations 
Total Y concentration (mol L–1) 1 × 10–3 1 × 10–2 1 × 10–1 1 × 100 1 × 101 1 × 102
Y- EDTMP 0.0 0.3 2.4 19.9 71.3 96.1
Y- Citrate 98.2 98.2 98.2 98.2 98.2 98.2
Y- Oxalate 0.8 0.8 0.8 0.8 0.8 0.8 
Y- Lactate 0.4 0.4 0.4 0.4 0.4 0.4 
Y-Amino acids 0.2 0.2 0.2 0.2 0.2 0.2 %
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If F is column vector of fi then improved values of
[Ri](=X) are calculated by Newton-Raphson method:
formula (3)
formula (4)
The method requires the computation of the Jaco-
bian matrix J, that is the matrix of partial derivatives of
each functions f, with respect to each unknown variables
X. The shift vector δX is obtained by solving the equation
3 applying the method of LU decomposition. The solution
vector has the form:
formula (5)
where h is indicator of the iteration. Equations (4) and (5)
are applied repeatedly until convergence of functions F
and variable X is reached. The Jacobian J is calculated al-
gebraically and numerically by finite approximation equa-
tion. The method is subject to problems if J is nearly sin-
gular or if highly nonlinear system with more than five
equation is present. These troubles are partially overcome
by using the numerical procedures of dumping. scaling
and convergence forcer.
In developing the computer modeling of blood pla-
sma we improved May et al model of blood plasma and
constructed multi-phase model including 9 metals, 43 li-
gands and over 6100 complexes. Total concentrations of
all components were taken from published papers and
Geigy tables.56,48–58,63 Almost all stability constants of bi-
nary and ternary complexes were abstracted from publis-
hed databases (JESS, IUPAC, NIST) and where necessary
converted to physiological conditions (T=310 K, I= 0.15
mol L–1 NaCl) using the program SIT(Specific Interaction
Theory).64–66 Part of the stability constants was updated on
the basis of recent literature data.
2. Results and Discussion
2. 1. Aluminum in Human Blood Plasma
Model
The physiological model of human blood plasma is
based on May et al computer model of blood plasma.56 To
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this model aluminum species were added either from refe-
rence databases or published data. If no constants were
available in the literature, values were estimated using
LFER approach between Al3+ and Fe3+ ions. Essential step
in simulations is selection of total Al-concentration in pla-
sma and extent of its binding to transferrin. Inclusion of
transferrin binding in calculations leads to decrease of
LMM species concentration but their relative distribution
remains constant. The effect of transferrin is to decrease
the amount of Al3+ available for the LMM species pool.
Jackson found that at pH 7.4 within the total Al concentra-
tion range 10–13 – 10–5 mol L–1 free Al concentration in
plasma is approximately ∼ 10–9 [Al3+]total taking into ac-
count upper level of soluble Al concentration (as set by
precipitation of Al(OH)3 and AlPO4) as well as binding to
transferrin (50% saturation). At total Al concentration 1
μmol L–1 this means free Al concentration 10–15 mol L–1.
Thus, insoluble Al species and formation of Al – transfer-
rin complex may not be included in calculations. Other se-
rum proteins, notably albumin, so weakly bind to Al that
these interactions could safely be neglected.67 To take into
account the formation of labile species, which are depen-
ded on level of Al concentration, we scanned the concen-
tration range between 10–15 to 10–3 mol L–1. The calcula-
ted distribution of the species in blood plasma is given in
Table 5A. It appears that soluble mixed hydroxo phospha-
te species of aluminum is the dominating one as found in
earlier works. Citrate species in the form of mixed phosp-
hate and hydroxo complexes account for about 30% of to-
tal Al. In the broad concentration range of Al this distribu-
tion does not change significantly. Only at higher Al con-
centration hydroxide species gradually become more im-
portant.
Ternary complexes AlCitPO4 and AlCitPO4OH are
new species that occur as a result of calculation which did
not appear in previous computer studies. A review of pub-
lished computer simulations of the speciation of alumi-
num in serum shows that some studies predicted that citra-
te would be the main LMM ligand whereas other predic-
ted that phosphate would be more important Al LMM bin-
ding agent. These difficulties mainly arise from the fact
that aluminum speciation was calculated at pH 7.4 from
the data derived at much lower pH values. Also the expe-
rimental studies use the total concentrations of Al 1000
and more times higher than the physiological ones. These
difficulties were reduced in a recent study of Harris et al.,
on Al speciation in serum.55 The effective binding con-
stants for Al-citrate and Al-phosphate have been determi-
ned at pH 7.4 and total Al concentration 10 μmol L–1. We
added the relevant data into our database and repeated the
speciation calculations excluding non-relevant Al-phosp-
hate species. The obtained distribution of Al-species is
shown in Table 5B.
It can be seen that the mixed complex Al(PO4)Cit is
the dominating species, while Al(PO4) accounts for only
0.01% of LMM Al species. Thus, of the pool of LMM alu-
minum species, 83% of the aluminum is bound to citrate
in mixed and binary complexes. The mixed hydroxo
phosphate-Al species appear to be much less important
than in a previous model. 
In evaluating the obtained results it must be taken
into account that the biological fluids are open systems
which never reach true thermodynamic equilibrium. Thus,
the speciation of metal ions particularly aluminum, is time
dependent process. Recently, the time dependent specia-
tion of Al was calculated using the data of pH dependence
on time in solutions containing Al3+ ion, citrate and
phosphate ligands.68 The results of calculations indicate
that the ternary mixed Al-citrate-phosphate species predo-
minate over time until true equilibrium is reached. If
phosphate is added in excess to a solution of trinuclear Al-
citrate, the phosphate slowly displaces the citrate from the
complex.69 Thus, at physiological pH phosphate appears
as efficient binder of Al. This agrees with Bantam et al.,
findings in their experiments with Al(NO3)3 spiked serum
that three main Al species in serum are Al-citrate, Al-
phosphate and ternary Al-citrate-phosphate complex.70 Ti-
me dependent distribution of Al3+ in serum was elaborated
by Beardmore and Exley.71 Their model predicted signifi-
cant role and existence of Al-hydroxide phase which is
Table 5. Calculated bio-distribution of Al(III) species in human blood plasma using different sets of LMM – Al complexes. A: Harris’s model of
LMM-Al complexes,53 B: Harris et al model of LMM-Al complexes.55
Total Al concentration (mol L–1) 1 × 10–15 5 × 10–13 1 × 10–11 1 × 10–9 1 × 10–5 1 × 10–3
Al(PO4)(OH) 88.5 88.5 88.5 88.5 88.3 37.2
AlCit(OH) 9.1 9.1 9.1 9.1 9.2 10.3
A Al(OH)3 1.3 1.3 1.3 1.3 1.3 35.6
Al(OH)4 0.5 0.5 0.5 0.5 0.5 15.2
AlPO4 0.5 0.5 0.5 0.5 0.5 0.2
Al(PO4)Cit 40.7 40.7 40.71 40.71 39.9 41.4
AlCit (PO4)(OH) 22.9 22.9 22.9 22.9 22.4 28.8
B AlCit(OH) 19.2 19.2 19.2 19.2 19.2 17.6
Al(PO4)(OH) 12.7 12.7 12.7 12.7 13.4 7.2
Al(OH)3 2.6 2.6 2.6 2.6 2.9 2.2
Al(OH)4 1.1 1.1 1.1 1.1 1.2 1.2
%
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consistent with the formation of insoluble ternary Al-
hydroxide-phosphate phase as found in computer models.
It follows therefore, that kinetic route to equilibrium di-
stribution of LMM species of Al in serum indicates very
important role of phosphate as a competent binder of Al,
forming predominantly ternary complexes.
2. 2. Gadolinium in Human Blood Plasma
Model
Gadolinium complexes included in speciation are
given in Table 6. Binding of Gd(III) to serum albumin was
also considered. About 100 gadolinium complexes with
Table 6. The soluble Gd(III) species distribution in human blood plasma 
Total Gd concentration (mol L–1) 1.2 × 10–9 1 × 10–8 1 × 10–7 1 × 10–6 1 × 10–5 1 × 10–4 1 × 10–3 1 × 10–2
GdCitAsp 29.39 7.15 0.72 0.07 0.01 – – –
GdCit(OH)2 20.14 4.90 0.49 0.05 0.01 – – –
GdCitLac 11.93 2.90 0.29 0.03 0.00 – – –
GdCitHisH2 10.47 2.55 0.25 0.03 0.00 – – –
GdHSA 7.88 1.92 0.19 0.02 0.00 – – –
GdCitLeu 3.04 0.74 0.07 0.01 0.00 – – –
GdCit 2.78 0.68 0.07 0.01 0.00 – – –
GdCitGlnH2 2.42 0.59 0.06 0.01 – – –
GdOxa 1.99 0.48 – – – – – –
GdGlyCit H2 1.65 0.40 – – – – – –
GdGluCit 1.20 0.29 – – – – – –
GdAlaCitH2 1.16 0.28 – – – – – –
GdValCitH2 1.15 0.28 – – – – – –
GdCit(OH) 0.96 0.23 – – – – – –
Gd(CO3)2 0.69 0.17 – – – – – –
GdHAspCit 0.58 0.14 – – – – – –
GdHGlnCit 0.51 0.12 – – – – – –
Gd2(CO3)2 (s) 0.00 0.00 0.00 0.00 0.00 0.00 73.82 96.94
GdPO4 (s) 0.00 75.67 97.57 99.76 99.98 100.00 26.18 3.06
Table 7. Stability constants of Yttrium complexes used in blood plasma model
Y-LMM 
logβp.q.r
Y-LMM 
logβp.q.r
Y-LMM 
logβp.q.r
Y-LMM 
logβp.q.rspecies species species
YH–1 –7.80 YHis 3.00 YHCit 9.30 YAsn 5.46
YH–2 –14.04 YLeu 6.09 YCit 6.80 YAsn2 6.58
YH–2 –17.00 YLeu2 8.16 YLys 3.10 YAsp 4.75
YH–3 –26.0 YAla2 8.09 YH2Cit 10.86 YAsp2 8.42
Y3H–5 –33.8 YSal 8.68 YCit2 10.17 YSer 5.53
Y4H–6 –32.0 YTrp 5.48 YLac 2.80 YHSer 3.50
Y(SCN) 1.60 YH2(PO4) 4.30 YLac2 5.33 Y(CO3) 5.71
Y(SCN)2 2.90 YTyr 2.90 YLac3 6.95 Y(CO3)2 10.33
Y(SCN)3 3.40 YHTyr 4.43 YSal 8.68 Y2(CO3)2 6.98
Y(SO4) 3.51 YCys 4.90 YAla 5.42 YPro 5.50
Y(SO4)2 5.34 YGlu 4.82 YMet 5.72 YPro2 10.21
YOxa 5.74 YGln 4.72 YPhe 3.49 YH–3(s) 19.9
YOxa2 10.09 YGln2 8.05 YVal 4.79 YPO4(s) 16.98
YGly 5.06 YTrp 3.70 YVal2 9.06 Y2(CO3) 3(s) –31.52
YMal 4.60 YIle 6.11 YThr 3.70
YHMal 8.14 YCys 4.90 YHypro 4.52
YMal2 7.56 YArg 3.20 YHypro2 8.92
%
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blood plasma ligands as well as insoluble species
Gd2(CO3)3 and Gd(PO4) were included. A total concentra-
tion of gadolinium in blood plasma model was scanned
from 1.2 × 10–9 to 1.0 × 10–2 mol L–1, that is from normal
serum level of gadolinium to much higher concentration
levels.72 High concentration levels were tried to observe
trends in species formation. The results obtained with Hy-
SS2009 calculation are shown in Table 6.
Main soluble complexes in blood plasma appears to
be the mixed ternary complex GdAspCit. Binding to albu-
min accounts for about 7.5% of total gadolinium concen-
tration. The distribution of the Gd(III)-ion in plasma com-
plexes has been calculated with different Gd(III)-ion con-
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centration ranging from 1.2 × 10–9 to 1.0 × 10–2 mol L–1.
Increasing the concentration of Gd(III) leads to decrease
of the dominant complex concentration favoring the
appeareance of insoluble species. The GdPO4(s) begins to
form at low gadolinium concentrations and its relative
percentage increases with increasing the total Gd concen-
tration. It becomes the only species at Gd(III) concentra-
tion of 1 × 10–4 mol L–1 and higher. Only the solids, Gd-
carbonate and Gd –phosphate are present in the system.
Carbonate solid phase is competitor to phosphate only at
milimolar concentrations of Gd. Thus GdPO4(s) and
Gd2(CO3)3(s) are the dominant species in a wide range
Gd(III)-ion concentration consistent with the tendency
lanthanides to form insoluble complexes with phosphates
and carbonates.
2. 3. Yttrium in Human Blood Plasma Model
So far there is very little results of Y(III) speciation
in human blood plasma. In this work we included about
65 Y-LMM complexes with total concentration of Y(III)-
ion 1 × 10–9 mol L–1. Complexes used in simulation are
shown in Table 7 and the results of HySS2009 calculation
are shown in Table 8.
Main soluble complex in blood plasma appears to be
the complex YCit. Increasing of the concentration of
Y(III) leads to decrease of the dominant complex concen-
tration favoring the appeareance of insoluble species. The
distribution of the Y(III)-ion within plasma complexes has
been calculated with different Y(III)-ion concentration
ranging from 1.0 × 10–9 to 1.0 × 10–3 mol L–1. Dominant
Y(III) complexes in serum calculated by HySS2009
shown in Table 8.
From Table 8 it can be seen that increasing the total
concentration of yttrium leads to appearance of insoluble
species. Y2(CO3)3(s) becomes the dominant species at Y(III)
concentration range from 1 × 10–6 to 1 × 10–3 mol L–1.
3. Conclusion
The computer simulation of speciation of Al3+, Gd3+
and Y3+ ions in human plasma using the program
Hyss2009, indicate that the main binding plasma ligand is
Table 8. Dominant Y(III)-complexes in serum at different concentrations of yttrium
Total Y concentration (mol L–1) 1 × 10–9 1 × 10–8 1 × 10–7 1 × 10–6 1 × 10–5 1 × 10–3
YCit 47.63 47.63 47.62 6.27 0.49 5.04
Y(CO3)2 32.49 32.49 32.5 4.28 0.33 5.93
Y(CO3) 10.60 10.61 10.61 1.40 0.11 2.06
YCit2 2.98 2.98 2.98 0.39 0.03 0.16
YOxa 1.57 1.57 1.57 0.21 0.02 0.24
Y2(CO3)3(s) 0 0 0 86.84 98.98 85.64
%
 Y
-L
M
M
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citrate forming binary and/or ternary complexes with me-
tal ions. Upon increasing the total concentration of metal
ions hydroxide complexes become more important. Con-
tribution of phosphate complexes to the Al speciation
strongly depends on equilibrium Al – phosphate data inc-
luded in computer simulation. Phosphate does not appear
to be important binder of Al3+ ion if set of complexes inc-
luded in computer model comprised only the species rele-
vant to physiological conditions. However, if the included
set of complexes was derived from LFER approximation
of equilibrium measurements made in a broader pH range,
then mixed hydroxo or citrate ternary Al – phosphate
complexes appear as the important species. All three me-
tal ions show similar, behavior in blood plasma with re-
gard to citrate binding. Citrate species are the main ones
for all three metal ions forming either binary or ternary
complexes. Presence of insoluble complexes is characteri-
stic for studied metal ions and depends upon total concen-
tration of metals.
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4. 1. Abbrevations
ICP-MS Inductively coupled plasma
ETAAS Electrothermal atomic absorption spectro-
metry
AMS Accelerator mass spectrometry
GFC-FAAS Graphite furnace atomic absorption spec-
trometry
FPLC Fast protein liquid chromatography
MRI Magnetic resonance imaging
ICP-OES Inductively Coupled Plasma-Optical Emis-
sion Spectrometer
LFER Linear free energy relationship
LMM Low molecular mass
HMM High molecular mass
Tfn Transferrin
HSA Human serum albumin
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DTPA Diethylenetriaminepentaacetic acid
DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid
EDTMP Ethylenediaminetetramethylphosphonic
acid
Amino acid Standard abbreviations 
residues
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Povzetek
Preu~evali smo speciacijo Al3+, Gd3+ in Y3+ ionov v ~love{ki plazmi z ra~unalni{ko simulacijo ob uporabi programa Hy-
SS2009. Posodobili smo ra~unalni{ki model iz literature in zajeli 9 kovin, 43 ligandov ter preko 6100 kompleksov. K te-
mu modelu smo dodali kriti~no presojene podatke za konstante Al3+, Gd3+ in Y3+ z ligandi iz krvne plazme. Nizkomole-
kularna (LMM) speciacija Al3+ iona je zelo odvisna od izbranega ravnote`nega modela za sisteme kovina–fosfat in ko-
vina–citrat. Dobljene ra~unalni{ke simulacije LMM speciacijskih podatkov so: AlPO4Cit (40,7%), AlPO4CitOH
(22,9%), AlCitOH (19,2%) in AlPO4(OH) (12,7%) (% skupnih LMM Al zvrsti); za Gd
3+ ion: GdAspCit (30%) in Gd-
Cit(OH)2 (20%) (% skupne [Gd]) in za Y3+ ion: YCit (48%), Y(CO3)2 (32%) in Y(CO3) (11%) (% skupne [Y]). Citrat se
pojavlja kot pomemben ligand za vezavo in mobilizacijo preu~evanih ionov, medtem ko so dominantne zvrsti ternarne-
ga tipa.
